We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $519M Turnover 37.5%
1-Year Est. Return 339.42%
This Fund
S&P 500
This Quarter Est. Return
+19.97%
1 Year Est. Return
+339.42%
3 Year Est. Return
+563.8%
5 Year Est. Return
+1,003.88%
10 Year Est. Return
–
AUM
$519M
AUM Growth
+$239M
Cap. Flow
+$170M
Cap. Flow %
32.7%
Top 10 Hldgs %
100%
Holding
8
New
2
Increased
1
Reduced
1
Closed
1
Avg Time Held
2.9 years
Top 10 Avg Time Held
2.9 years
Top 20 Avg Time Held
2.9 years

Top Buys

Rank Stock Value
1
PBLS
Parabilis Medicines Inc
PBLS
+$145M
2
ACHV icon
Achieve Life Sciences
ACHV
+$28.2M
3
PHVS icon
Pharvaris
PHVS
+$125K

Top Sells

Rank Stock Value
1
ARTV icon
Artiva Biotherapeutics
ARTV
+$3.42M
2
HRMY icon
Harmony Biosciences
HRMY
+$536K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PHVS icon
1
Pharvaris
PHVS
$2.09B
$161M 30.92%
4,643,430
+4,126
+0.1% +$125K
2021 Q1
21 quarters
PBLS
2
Parabilis Medicines Inc
PBLS
$3.23B
$144M 27.75%
+5,266,697
New +$145M
2026 Q2
0 quarters
ALMS icon
3
Alumis Inc
ALMS
$815M
$127M 24.53%
4,528,408
– –
2024 Q2
8 quarters
ACHV icon
4
Achieve Life Sciences
ACHV
$713M
$38.6M 7.44%
+5,914,720
New +$28.2M
2026 Q2
0 quarters
ALXO icon
5
ALX Oncology
ALXO
$127M
$26.7M 5.14%
12,884,638
– –
2020 Q3
23 quarters
HRMY icon
6
Harmony Biosciences
HRMY
$2.25B
$17.2M 3.31%
472,194
-17,000
-3% -$536K
2020 Q3
23 quarters
LYEL icon
7
Lyell Immunopharma
LYEL
$203M
$4.74M 0.91%
337,697
– –
2024 Q4
6 quarters
ARTV icon
8
Artiva Biotherapeutics
ARTV
$295M
– –
-531,337
Closed -$3.42M –

Similar funds

CFA
Churchill Financial Advisors Louisville, Kentucky $519M AUM
CFG
Compton Financial Group Towson, Maryland $519M AUM 14.76% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $519M AUM 46.03% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $520M AUM 21.73% 1-Year Est. Return
WS
Wendel SE Paris $519M AUM 48.2% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
MWC
MBM Wealth Consultants Chesterfield, Missouri $519M AUM 16.88% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $518M AUM 22.62% 1-Year Est. Return

venBio Partners's Q2 2026 Portfolio in Review

As of Q2 2026, venBio Partners held 8 positions worth $519M, up 85% from $281M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners deployed $170M of net new capital in Q2 2026, opening 2 new positions and adding to 1 existing holding. Its largest new stake was Parabilis Medicines Inc: 5,266,697 shares worth $144M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Harmony Biosciences, an estimated $536K trimmed.

  • venBio Partners's largest Q2 2026 buy was Parabilis Medicines Inc: 5,266,697 shares worth $144M.
  • venBio Partners added most to Pharvaris in Q2 2026, an estimated $125K increase.
  • venBio Partners's biggest Q2 2026 reduction was Harmony Biosciences, cutting an estimated $536K.
  • venBio Partners fully exited Artiva Biotherapeutics in Q2 2026, selling an estimated $3.42M.
  • venBio Partners's ten largest holdings make up 100% of its $519M portfolio in Q2 2026.
  • venBio Partners opened 2 new positions and closed 1 in Q2 2026.
  • venBio Partners's portfolio value rose 85% quarter-over-quarter to $519M.

Based on venBio Partners's 13F filing for Q2 2026, filed 14 Aug 2026.